- Mikael Dolsten will not seek election to Novo Nordisk's Board at the 14 November 2025 meeting.
- Dolsten's withdrawal is due to personal reasons unrelated to Novo Nordisk.
- No replacement candidate will be proposed until the Annual General Meeting on 26 March 2026.
- Current board candidates remain as announced in the 21 October 2025 notice.
Board Candidacy Withdrawal
Mikael Dolsten, previously Head of R&D at Pfizer, has decided not to pursue election to the Novo Nordisk Board of Directors at the extraordinary general meeting on 14 November 2025. His decision is attributed to personal circumstances unrelated to Novo Nordisk or its foundation.
Future Board Plans
The Novo Nordisk Foundation and Novo Holdings A/S have announced they will not propose a replacement candidate for Dolsten at the upcoming meeting. Instead, they plan for the new Board to nominate two additional candidates, alongside Helena Saxon, at the Annual General Meeting on 26 March 2026.
Current Board Candidates
The other candidates for the Board, as announced in the 21 October 2025 notice, remain unchanged. If elected, the Board will include Lars Rebien Sørensen as Chair, Cees de Jong as Vice Chair, and other shareholder and employee-elected members.
